Saturday 17 October 2026
Export BBIO’s income statement to Excel — free account
BridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024. In the quarter to June 2026, revenue grew 120.4%, EPS grew 17.9%, free cash flow grew 16.6% and total debt rose 4.22%, each against the same quarter a year earlier.
66.39
0.74
−1.10%
Follow BBIO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 6 | 1 | 4 | 3 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
29.18 | 23.01 | 707.83 | 13.62 | 34.54 | 171.91 | 0.00 | — | — |
Altman Z-Score |
(3.45) | (4.57) | (7.39) | (5.71) | (2.13) | 5.38 | 12.66 | — | — |
Altman Z″-Score (non-manufacturers) |
(14.22) | (11.92) | (19.49) | (11.76) | (4.05) | (3.36) | 3.32 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
(259.66) | (26.14) | (52.76) | (11.34) | (17.98) | (87.17) | (48.34) | — | — |
Beneish M-Score |
8.17 | 17.52 | (5.72) | (3.26) | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 78.97 | 7.78 | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 78.97 | 7.78 | — | — |
EV/Sales |
31.71 | 27.71 | 845.29 | 29.09 | 47.03 | 169.25 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(35.70) | (11.81) | (14.90) | (5.38) | (6.58) | (20.67) | (12.77) | — | — |
EV/FCF |
(34.94) | (11.61) | (14.82) | (5.30) | (6.41) | (20.29) | (12.64) | — | — |
Quick Ratio |
2.52 | 4.44 | 3.15 | 4.34 | 6.34 | 6.35 | 9.09 | 13.39 | 10.22 |
Current Ratio |
2.77 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | 10.78 |
Net Debt/EBITDA |
(2.47) | (1.80) | (2.15) | (2.37) | (1.52) | 0.27 | 1.68 | 2.08 | (1.19) |
Debt/Assets |
197.91% | 187.24% | 316.03% | 274.08% | 168.23% | 67.84% | 15.80% | 11.72% | 0.00% |
Debt/Equity |
(0.89) | (1.18) | (1.29) | (1.37) | (1.97) | 4.49 | 0.21 | 0.14 | 0.00 |
Asset Turnover |
0.54 | 0.30 | 0.02 | 0.09 | 0.08 | 0.01 | 0.07 | 0.00 | 0.00 |
Operating CF/Net income |
0.62 | 0.97 | 0.82 | 0.87 | 0.89 | 0.89 | 0.97 | 1.05 | 1.32 |
Capex/Depreciation |
(0.84) | (0.66) | (0.08) | (0.93) | (8.26) | (5.16) | (3.07) | 0.00 | (1.78) |
Interest Coverage |
(2.94) | (5.97) | (7.47) | (6.37) | (12.33) | (12.94) | (30.38) | (72.11) | (3,373.69) |
| 41.03% | 38.26% | 49.74% | 45.60% | 147.89% | (154.74%) | (61.24%) | (82.69%) | (24.07%) | |
| (78.14%) | (73.11%) | (110.00%) | (58.83%) | (65.55%) | (67.21%) | (47.53%) | (56.24%) | (10.86%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (604.41%) | 0.00% | (52.71%) |
Return on Tangible Assets |
(140.72%) | (93.45%) | (186.13%) | (108.87%) | (71.77%) | (79.07%) | (50.71%) | (31.57%) | (34.73%) |
Average Days of Receivables |
101.37 | 7.77 | 68.70 | 80.28 | 103.40 | 0.00 | 25.60 | — | — |
Research and Development Expense of Revenue |
90.02% | 228.24% | 4,898.54% | 514.45% | 646.94% | 4,085.91% | 517.62% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
105.81% | 130.21% | 1,618.73% | 184.41% | 275.70% | 1,766.08% | 232.63% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.05 | 0.05 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
26.49% | 43.17% | 1,168.55% | 117.92% | 142.73% | 708.68% | 52.70% | 0.00% | 0.00% |
Graham Net Nets |
(0.15) | (0.32) | (0.21) | (1.25) | (0.41) | 0.01 | 0.11 | — | — |
Graham Number |
30.36 | 22.41 | 27.04 | 24.91 | 22.99 | 0.00 | 0.00 | — | — |
Earnings Yield |
(4.94%) | (10.39%) | (9.74%) | (45.61%) | (23.44%) | (5.34%) | (7.65%) | — | — |
Free Cash Flow Yield |
(3.11%) | (10.37%) | (8.06%) | (40.27%) | (21.23%) | (4.85%) | (6.96%) | — | — |
Revenue per Share |
2.62 | 1.19 | 0.06 | 0.53 | 0.48 | 0.07 | 0.39 | 0.00 | 0.00 |
Operating CF per Share |
(2.33) | (2.80) | (3.24) | (2.84) | (3.45) | (3.39) | (2.41) | (2.21) | (1.32) |
Capex per Share |
(0.05) | (0.05) | (0.01) | (0.04) | (0.33) | (0.06) | (0.03) | (0.04) | (0.02) |
Free Cash Flow per Share |
(2.38) | (2.85) | (3.25) | (2.89) | (3.78) | (3.45) | (2.44) | (2.25) | (1.34) |
Cash per Share |
3.07 | 3.66 | 2.77 | 3.46 | 5.80 | 5.15 | 5.20 | 7.06 | 3.01 |
Shareholders Equity per Share |
(10.84) | (7.83) | (8.25) | (8.43) | (6.01) | 0.90 | 4.51 | 6.11 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(10.84) | (7.83) | (8.25) | (8.43) | (6.01) | 0.90 | 4.51 | 6.11 | 0.00 |
Free Cash Flow |
(455.50) | (529.63) | (529.03) | (425.81) | (546.18) | (407.23) | (256.22) | (138.82) | (40.95) |
Working Capital |
509.78 | 566.29 | 333.75 | 427.43 | 753.79 | 547.18 | 508.24 | 412.65 | 88.00 |
Capital Expenditures |
(9.59) | (8.91) | (1.31) | (6.32) | (48.25) | (7.52) | (2.64) | (2.18) | (0.46) |
Net Current Asset Value |
(2,214.29) | (1,656.40) | (1,411.80) | (1,317.52) | (990.94) | 45.49 | 410.68 | 357.52 | 97.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.02 | 0.04 | 0.14 | 0.08 | 0.69 | 0.91 | 0.07 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
2.12 | 1.93 | 1.30 | 0.46 | 0.19 | 0.07 | 0.15 | 0.00 | 0.00 |
Cash ROIC |
(125.16%) | (56.06%) | (63.34%) | (43.71%) | (32.63%) | (34.20%) | (22.89%) | (16.00%) | (17.35%) |
Accounts Receivable Turnover |
6.97 | 68.56 | 0.99 | 4.22 | 6.17 | 0.00 | 3.55 | — | — |
Accounts Payable Turnover |
0.91 | 0.38 | 0.22 | 0.29 | 0.30 | 0.35 | 0.22 | 0.00 | 0.03 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Days of Payables |
630.82 | 905.25 | 1,589.97 | 1,228.50 | 1,392.95 | 1,057.29 | 1,292.39 | 0.00 | 2,807.69 |
Days of Inventory on Hand |
465.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Receivables |
72.08 | 3.24 | 9.42 | 18.41 | 11.30 | — | 11.42 | — | — |
Average Payables |
22.92 | 10.14 | 11.11 | 11.72 | 10.41 | 8.90 | 11.18 | 7.75 | 8.00 |
Average Assets |
927.68 | 732.86 | 584.71 | 817.91 | 858.19 | 667.63 | 548.31 | 232.47 | 281.50 |
Average Common Equity |
(1,766.88) | (1,400.38) | (1,293.17) | (1,055.17) | (380.37) | 289.99 | 425.49 | 158.12 | 127.00 |
Columns are period end dates